TANGO THERAPEUTICS INC (TNGX) Stock News

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences

BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to...

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...

Unveiling 5 Analyst Insights On Tango Therapeutics

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

The Analyst Landscape: 5 Takes On Tango Therapeutics

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

Tango Therapeutics Announces Discontinuation of TNG348 Program

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the first quarter of...

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q1 2024

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tango Therapeutics (NASDAQ:TNGX) just reported results for the fourth quarter o...

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023

TNGX stock results show that Tango Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...